Form 4: RA Capital Affiliates Report Grant of 46,000 Stock Options in Nkarta, Inc. to Board Director

RA Capital Management, L.P. and its affiliated funds, along with managing members, reported the grant of 46,000 stock options in Nkarta, Inc. to Dr. Zachary Scheiner, a Principal of RA Capital and a director on Nkarta's board, with an exercise price of $1.83 per share.

Summary

• RA Capital Management, L.P., its affiliated funds (RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P.), and managing members Peter Kolchinsky and Rajeev Shah, filed a Form 4 regarding Nkarta, Inc. (NKTX).
• The filing reports the grant of 46,000 stock options to Dr. Zachary Scheiner, a Principal of RA Capital and a director on Nkarta's board.
• The options have an exercise price of $1.83 per share and were granted on June 5, 2025, with an expiration date of June 4, 2035.
• The options vest 100% on the earlier of June 5, 2026, or the day immediately preceding the first annual meeting of stockholders after the grant date, subject to Dr. Scheiner's continued service.
• Full vesting also occurs upon a 'change in control' of Nkarta, Inc. or Dr. Scheiner's separation due to death or 'disability'.
• Dr. Scheiner holds these options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., and is obligated to turn over any net proceeds to the Adviser, offsetting advisory fees.
• The reporting persons disclaim beneficial ownership of the option and underlying common stock, except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The grant of stock options to a director, especially one affiliated with a significant investor like RA Capital, is generally a positive signal as it aligns interests and incentivizes long-term performance. While not a direct purchase of shares, it indicates confidence and commitment from a key stakeholder. The disclaimers of beneficial ownership are standard for investment managers holding options for their funds.

Positives

• The grant of stock options to a director aligns the director's interests with shareholder value creation.
• The vesting schedule encourages long-term commitment from the director.
• The exercise price of $1.83 provides a clear benchmark for future stock performance relative to the grant date.

Risks

• The value of the options is dependent on Nkarta, Inc.'s stock price exceeding the exercise price of $1.83.
• Vesting is subject to Dr. Scheiner's continued service, meaning the options could be forfeited if service ceases before vesting conditions are met (unless due to specific events like change of control, death, or disability).

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider equity transaction.

Management Comments

• Dr. Zachary Scheiner is a Principal of the Adviser who serves on the Issuer's board of directors.
• Under Dr. Scheiner's arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund and the Nexus Fund.
• Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser.
• Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

Industry Context

This Form 4 filing details an equity compensation event for a director of Nkarta, Inc., a biotechnology company. Such grants are standard practice in the biotech industry to attract and retain talent, particularly for board members who often bring specialized expertise and strategic guidance. The involvement of RA Capital, a prominent healthcare investment firm, highlights continued alignment between institutional investors and company governance.

Comparison to Industry Standards

• The grant of stock options to board directors is a common practice in the biotechnology and pharmaceutical industries, aligning director incentives with long-term shareholder value.
• The exercise price of $1.83 per share is specific to Nkarta's current valuation and market conditions at the time of grant, and its competitiveness would be assessed against peer company director compensation packages and stock performance at similar stages of development.
• The vesting schedule, tied to continued service and accelerated by change of control, is typical for equity awards in the sector, designed to retain key personnel and provide liquidity upon strategic events.

Related Party Transactions

• The stock option grant to Dr. Zachary Scheiner, a director of Nkarta, Inc., is considered a related party transaction as Dr. Scheiner is also a Principal of RA Capital Management, L.P., which is a 10% owner and investment manager for funds that are also reporting persons.
• Dr. Scheiner holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., and is obligated to remit net proceeds to RA Capital Management, L.P., which offsets advisory fees.

Stakeholder Impact

• Shareholders: The option grant aligns the interests of a key director and a significant institutional investor (RA Capital) with long-term shareholder value creation. The exercise price provides a target for stock appreciation.
• Management/Employees: The grant to a director reinforces the company's commitment to attracting and retaining experienced board members.

Next Steps

• Dr. Scheiner's continued service to Nkarta, Inc. through the vesting date (earlier of June 5, 2026, or the day preceding the first annual meeting after grant) is required for the options to vest.
• The options will become fully vested upon a 'change in control' of Nkarta, Inc. or Dr. Scheiner's separation due to death or 'disability'.
• Upon exercise, Dr. Scheiner is obligated to turn over net cash or stock to RA Capital Management, L.P., which will offset advisory fees owed by the affiliated funds.

Key Dates

Recommendation

Keywords

Nkarta Inc., NKTX, SEC Form 4, Stock Option Grant, Insider Transaction, RA Capital Management, Director Compensation, Equity Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals